Abstracts tagged "veterans"

Abstract Number: 1143 • ACR Convergence 2021
Predictors of Engagement in Bone Health Care Among Rural Veterans at Risk for Osteoporosis
Karla Miller¹, Kimberly McCoy², Christopher Richards², Aaron Seaman³ and Samantha Solimeo⁴, ¹Department of Internal Medicine, Rheumatology Section, Veterans Affairs Salt Lake City Health Care System; Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT, ²VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation, Department of Veterans Affairs, CADRE, Iowa City VA HCS, Iowa City, IA, ³VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City (VRHRC-IC); Division of Genera l Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, ⁴VA Office of Rural Health, Veterans Rural Health Resource Center-Iowa City; Comprehensive Access & Delivery Research and Evaluation; and Primary Care Analytics Team Iowa City (PCAT-IC), Department of Veterans Affairs, CADRE, Iowa City VA HCS Division of General Internal Medicine, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA
Background/Purpose: A virtual bone health team (BHT) model was implemented to identify, screen, and treat rural Veterans at risk for osteoporosis. This study was conducted…
Abstract Number: 355 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Hanna Zembrzuska¹, Yubo Gao ¹, Saket Girotra ¹, Brian Lund ², Kenneth Saag ³, Jeffrey Curtis ³, Mary Vaughan-Sarrazin ² and Namrata Singh ⁴, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²Iowa City VA Health Care System, Iowa City, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Gout is the most common inflammatory arthritis and is particularly common among veterans. Recent studies, a randomized controlled trial (CARES, White et al. NEJM…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].